Summary.-C3H/HeJ mice bearing i.m. transplanted KHT sarcomas were treated with varying doses of either 1,3-bis(2-chloroethyl)-l-nitrosourea (BCNU) or 2-{3-(2-chloroethyl)-3-nitrosoureido}-D-glucopyranose (chlorozotocin; CHLZ) as single agents or in combination with 1 mg/g of the chemical radiosensitizer, misonidazole (MISO). Using an in vivo-in vitro tumour-excision assay, the administration of MISO simultaneously with or 3 h after low doses of BCNU ( < 20 mg/kg) was found to give a dose-modification factor (DMF) of P165 relative to BCNU alone. At higher doses of BCNU, there was less enhancement of cell kill. The DMF for tumour growth delay was likewise dependent on BCNU dose, continuously decreasing with increasing BCNU dose. In contrast, the anti-tumour activity of CHLZ, assessed by both clonogenic cell survival and tumour-growth delay, was not signficantly enhanced by the addition of MISO.
RECENT demonstrations of hypoxic tumour-cell chemoresistance have prompted the design and evaluation of experimental protocols combining commonly used anti-tumour agents with nitroimidazoles, which in addition to sensitizing hypoxic cells to radiation, have been shown to be preferentially cytotoxic to hypoxic cells (review by Adams, 1981) . Such chemotherapeutic combinations have been evaluated in several in vitro and in vivo model systems and found to enhance the effectiveness of many commonly used alkylating agents (Sutherland et al., 1979; Roizin-Towle & Hall, 1978; Rose et al., 1980; Clement et al., 1980; Tannock, 1980a, b; Mulcahy et al., 1981; Law et al., 1981) . In spite ofencouraging experimental results, combination chemotherapy with nitroimidazole radiation sensitizers will prove to be of therapeutic benefit only if the magnitude of the enhanced tumour response exceeds the enhancement of normal-tissue toxicities. Clonogenic and tumour-growth delay assays were therefore used in the current study to assess the degree of dose modification produced by two BCNU-MISO treatment protocols. The magnitude of tumour-response enhancement was then compared to the dose modification produced for marrow stem cells, determined by spleen-colony (CFU-S) assay (Till & McCulloch, 1961) and for gastrointestinal toxicity assayed by the LD50/7 technique.
For comparison with these BCNU investigations, and similar studies with CCNU (Schein et al., 1978) was also determined.
MATERIALS AND MVlETHODS
An inials and tumour systenm. All studies wrere done using 8-12-week-old female C3H/ HeJ mice purchased from Jackson Laboratories, Bar Harbor, Maine. KHT sarcoma cells (Kallman et al., 1967) were passaged in vivo every 2 weeks, and prepared from solid tumours by mechanical dissociation (Thomson & Rauth, 1974) . KHT tumour cells (2 x 105) wvere injected i.m. into the right limb. Animals were sorted and randomized into the appropriate control and experimental groups (7/group) when tumours had grown to 0-2-0-4 g. Drug treatmentt.-BCNU was initially dissolved in 100% ethanol at a concentration of 30 mg/ml. and then diluted to a final concentration of 1-5 mg/ml with physiological saline immediately before injection. CHLZ was dissolved directly in physiological saline (1-0 mg/ml) immediately before injection. MISOC was dissolved in phosphate-buffered saline at a concentration of 20 mg/ml. All drugs were administered i.p. MISO (1P0 mg/g body weight) was administered either simultaneously with. or 3 h after nitrosourea injection.
Tumour-yrowth delay. Marrow" was flushed from the femurs, nucleated cells counted, appropriate dilutions prepared and injected i.v. into the irradiated recipient mice. Eight or 9 days after cell injection, the spleens -were harvested and the number of colonies determined. Mean stem-cell survival and standard error were calculated according to Blackett (1975) . Gastrointestinal toxicity. Gastrointestinal toxicity was estimated by determining the number of animals which died during 7 days post-treatment. From these data. LD50/7 (lethal dose to 50% of the animals in 7 days) and confidence limits were calculated by fitting a logit bioassay (Berkson, 1955) and using Scheffe's discrimination intervals (Finney, 1978) .
RESULTS

Tumour response
The efficacy of combining MISO with either of 2 nitrosoureas, BCNU delay increased non-linearly with dose. As previously reported (Tannock, 1980b; Mulcahy et al., 1981; Fig. 2A . After singleagent treatment with BCNU, survival decreased linearly with increasing BCNU dose, up to a dose of 40 mg/kg (surviving fraction of 1 x 10-4). At higher BCNU doses still, there was a tail on the survival curve, suggesting a relatively resistant population of tumour cells. In contrast, the cell-survival dose-response curve for KHT tumour cells treated in vivo with MISO alone was dominated by a large shoulder, followed by a significant decrease in cell survival only at doses > 1 mg/g.
Cell survival was similarly determined after the in situ treatment of KHT tumours with either of the two BCNU-MISO injection schedules. As with growthdelay enhancement, cell kill was equally enhanced by MISO under both treatment conditions (Fig. 2B, P>0 .10). However, at survival levels below 1 x 10-4, a resistant tail on the survival curve was evident after both combined-drug treatments. By slope-ratio assay (Finney, 1978) the DMF for the initial linear portion of the survival curve, obtained by pooling the results of both MISO-BCNU combinations, was found to be 1-65 (95% CHLZ combined with simultaneous MISO or MISO 3 h later was assessed in the KHT sarcoma by tumour-growth delay (Fig. 3B ). Tumour-cell survival (Fig. 3A) was also determined after CHLZ alone or CHLZ + simultaneous MISO. It is apparent from these studies that CHLZ is less effective than BCNU in the KHT tumour system, and that the anti-tumour activity of this agent is not enhanced by the addition of MISO to the treatment protocol. Since cell-kill enhancement was absent for MISO combined with any dose of CHLZ, tumour growth-delay assays were only performed for MISO combined with one dose of CHLZ.
Normal-tissue response
In an attempt to estimate the potential therapeutic benefit of combining a nitroimidazole with a conventional antitumour agent, the enhancement of marrow and gastrointestinal toxicities by BCNU-MISO treatment were compared with the magnitude of the enhanced tumour response. CFU-S survival was measured by spleen-colony assay (Fig. 4) 
Drug fractionation
Because the DMF for tumour-growth delay on combining BCNU and MISO decreased rapidly with increasing BCNU dose, the possibility of therapeutic benefit appeared to be greater at lower BCNU doses. A single series of experiments was therefore designed to evaluate the feasibility of fractionating BCNU and MISO treatment. In these studies, the growth delay produced on combining MISO with 3 small daily doses (10 mg/kg) of BCNU was assessed, and compared to the delay when MISO was combined with the same total BCNU dose (30 mg/kg) in a single (Fig. 2A) is similar to that reported by Lin & Bruce (1972) for BCNU-treated KHTl' tumouirs.
The striking similarity in degree of enhancement produced by the 2 MISO-BCNU combinations is of interest,, particularly in relation to pot,ential mechanisms. We previously suggested that, the enhanced tumour response on combining MISO and BCNU might be due to altered phamacokinetics, of either MISO or BNCU . However, AMISO pharmacokinetics in mice treated simultaneously with MISO and BCNU are not significantly different from mice treated with MISO alone (Mulcahy et al., unpublished) . Tannock has reported that serum from mice treated simultaneously with BCNU and MISO 30 min before killing had activity against aerobic CHO cells similar to that of serum from animals treated with BCNU alone (Tannock, 1 980b) . These data suggest that BCNU pharmacokinetics are not substantially altered by simultaneous treatment with MISO. Furthermore, considering the short half-life of BCNU in serum, it seems unlikely that administration of MISO 3 h after BCNU could substantially alter BCNU pharmacokinetics. In the light of these considerations, it seems unlikely that, pharmacokinetic changes are entirely responsible for the enhanced tumour response to chemotherapy with MISO and BCNU under our administration schedules.
In contrast to the modest tumourresponse enhancement when MISO is combined with BCNU, and the markedl 840) enhancement when MISO is combined with CCNU ) the effectiveness of the third structurally related nitrosourea, CHLZ, was not significantly modified (Fig. 3) . It has recently been suggested that the differential enhancement of the anti-tumour effect of various nitrosoureas by MISO might be correlated with their carbamoylating activity (Mulcahy, 1982) . Carbamoylation has been related to inhibition of the repair of sublethal damage caused by alkylation (Wheeler, 1976) .
In conclusion, we have demonstrated that the anti-tumour effect of BCNU, but not of CHLZ, can be modestly enhanced by combination with MISO. For BCNU, the enhancement of tumour-growth delay decreases rapidly to extinction with increasing dose. Clonogenic cell-survival data suggest that this effect may be due to a population of tumour cells equally resistant to BCNU and BCNU-MISO combinations. Both MISO injection schedules produced the same tumour responses, whether assessed by growth delay or clonogenic-cell survival. Normal-tissue toxicities were also enhanced by the MISO-BCNU combinations, but less than in tumours treated with MISO and relatively low-dose BCNU. However, two simple dose-fractionation protocols, designed to take advantage of this differential enhancement at low BCNU doses, failed to improve the tumour response.
These studies suggest that combination chemotherapy of MISO with BCNU or CHLZ may not significantly enhance tumour response over norrnal-tissue response, particularly at large BCNU doses. Similar results for BCNU and MISO have recently been reported by Tannock (1 980b). However, in spite of the poor enhancement achieved with BCNU and the lack of enhancement with CHLZ, studies combining MISO with CCNU, and other chemical alkylators, demonstrate that this approach to combination chemotherapy may have significant therapeutic potential, and therefore warrants continued investigation.
